SCHEMBL7422358

SCHEMBL7422358

O=c1[nH]c2cc(I)ccc2c(=O)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.56
CFD P00746 1/20 0.56
MAOA P21397 8/20 0.47
MAOB P27338 8/20 0.47
GPR17 Q13304 1/20 0.38
ACHE P22303 2/20 0.38
OGT O15294 1/20 0.37
NOS1 P29475 3/20 0.37
NOS3 P29474 2/20 0.37
NOS2 P35228 2/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
ADRA2A P08913 1/20 0.37
TSHR P16473 1/20 0.37
THPO P40225 1/20 0.37
BLM P54132 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CCNB2 O95067 2/20 0.36
CDK1 P06493 2/20 0.36
CCNB1 P14635 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30339066 1.00 F2 (0.56) F2CFDMAOAMAOBGPR17
SCHEMBL31460362 0.85 MAOA (0.57) F2CFDMAOAMAOBACHE
SCHEMBL3132671 0.85 MAOA (0.57) F2CFDMAOAMAOBACHE
SCHEMBL31607095 0.78 F2 (0.56) F2CFDMAOAMAOBACHE
SCHEMBL1202554 0.78 F2 (0.56) F2CFDMAOAMAOBACHE
SCHEMBL31607092 0.78 F2 (0.56) F2CFDMAOAMAOBACHE
SCHEMBL12324556 0.78 F2 (0.56) F2CFDMAOAMAOBACHE
SCHEMBL3435898 0.78 NOS1 (0.62) F2CFDMAOAMAOBNOS1
SCHEMBL625761 0.78 LMNA (0.62) F2CFDNOS1NOS3NOS2
SCHEMBL30557808 0.78 LMNA (0.62) F2CFDNOS1NOS3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4730479-A2 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME Kyoto University (JP) 2026-04-22 EP disclosed
US-20250246685-A1 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME KYOTO UNIVERSITY (JP) 2025-07-31 US disclosed
WO-2025120994-A1 SECONDARY BATTERY NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY PROVIDED WITH SAME ステラケミファ株式会社 2025-06-12 WO disclosed
WO-2025095088-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY PROVIDED WITH SAID SOLUTION ステラケミファ株式会社 2025-05-08 WO disclosed
US-12191448-B2 Nonaqueous electrolyte solution for secondary battery, and secondary battery provided with said solution STELLA CHEMIFA CORPORATION (JP) 2025-01-07 US disclosed
EP-4428982-A1 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME Kyoto University (JP) 2024-09-11 EP disclosed
CN-118056309-A Flame-retardant nonaqueous electrolyte and secondary battery using same 国立大学法人京都大学 2024-05-17 CN disclosed
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 US disclosed
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 US disclosed
WO-2023079988-A1 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME 国立大学法人京都大学 2023-05-11 WO disclosed
WO-1997024119-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-10 WO disclosed
US-5604227-A EXCITATORY AMINO ACID ANTAGONIST; MONO, DI OR TRI-ACETYLATION OR ALKYLATION IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1997-02-18 US disclosed
US-5599814-A SUBSTITUTED PYRIDAZINO(4,5-B)QUINOLINES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1997-02-04 US disclosed
EP-0516297-B1 Pyridazinediones and their use in the treatment of neurological disorders ZENECA LTD (GB) 1996-10-30 EP disclosed
EP-0693067-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1996-01-24 EP disclosed
EP-0693067-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1995-12-12 EP disclosed
US-5441952-A Prevent binding of fibrinogen to blood platelets MERCK & CO., INC. (US) 1995-08-15 US disclosed
US-5389631-A A piperidinyl quinazoline or 1,3-benzodiazepine antiagglomerants of blood MERCK & CO., INC. (US) 1995-02-14 US disclosed
WO-1994022825-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1994-10-13 WO disclosed
EP-0516297-A1 Pyridazinediones and their use in the treatment of neurological disorders ZENECA LIMITED (GB) 1992-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, MDM2 F2 3544/4885CFD 3953/4885MAOA 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.